Xenoestrogens are a large and structurally diverse group of compounds, which can act as inappropriate estrogens and/or can interfere with the actions of endogenous estrogens such as estradiol (E~2~) or other reproductive steroids. Many studies have demonstrated that contamination of the environment or treatment with xenoestrogens can disrupt developmental programs to alter sexual phenotypes and reproductive functions. Examples of such disruptions are a decline in the sperm quality of fish, interference with the sexual development of alligators and turtles, disruption of pregnancies in laboratory animals, interference with blastocyst implantation, and inappropriately induced progesterone receptor expression and uterine weight increases \[reviewed in [@b57-ehp0112-001481]\]. In addition, environmental estrogens have been shown to inhibit the human sperm acrosomal reaction ([@b50-ehp0112-001481]), and xenoestrogens are also suspected of causing breast cancer cell and vaginal epithelial cell proliferation ([@b23-ehp0112-001481]; [@b26-ehp0112-001481]).

Most previous studies investigated the possible actions of xenoestrogens through classical nuclear estrogen receptors (ERs) modifying gene activity ([@b26-ehp0112-001481]; [@b29-ehp0112-001481]; [@b30-ehp0112-001481]; [@b42-ehp0112-001481]; [@b46-ehp0112-001481]). A variety of *in vivo* and *in vitro* screening assays have been applied to predict the estrogenic potential of xenoestrogens, including several receptor-reporter-gene assay systems in transfected mammalian or yeast cell lines ([@b4-ehp0112-001481]; [@b14-ehp0112-001481]; [@b18-ehp0112-001481]; [@b20-ehp0112-001481]; [@b21-ehp0112-001481]; [@b24-ehp0112-001481]; [@b29-ehp0112-001481]; [@b38-ehp0112-001481]; [@b56-ehp0112-001481]). However, these methods demonstrated that xenoestrogens act very weakly (only at concentrations 1,000- to 10,000-fold higher than E~2~), if at all, via genomic activation pathways. Other tests have been assumed to assess genomic responses, but may in fact be assays for either nongenomic or combination mechanisms. These include cell proliferation test systems ([@b18-ehp0112-001481]; [@b20-ehp0112-001481]; [@b43-ehp0112-001481]; [@b47-ehp0112-001481]), receptor binding assays for ER-α or ER-β ([@b17-ehp0112-001481]; [@b18-ehp0112-001481]; [@b24-ehp0112-001481]), and predictions of ligand binding affinity and conformation of ER complexes with xenoestrogens by computer modeling ([@b48-ehp0112-001481]; [@b52-ehp0112-001481]; [@b59-ehp0112-001481]).

In addition to the classical genomic pathway, steroids can produce rapid (within a few minutes after application) nongenomic signaling effects via second messenger systems, for example, Ca^2+^, K^+^, cAMP, and nitric oxide level changes; activation of G protein--mediated events; and stimulation of different types of kinases such as extracellular-regulated kinases (ERKs), phosphoinositide-3 kinase (PI3K), p38, and Jun kinase (Junk) ([@b2-ehp0112-001481]; [@b13-ehp0112-001481]; [@b15-ehp0112-001481]; [@b16-ehp0112-001481]; [@b19-ehp0112-001481]; [@b22-ehp0112-001481]; [@b33-ehp0112-001481]; [@b37-ehp0112-001481]; [@b40-ehp0112-001481]). Although the precise molecular mechanisms of nongenomic actions are not fully understood, it is known that some rapid E~2~ effects can be initiated by ligand binding to membrane-associated ERs (mERs) that have been shown to be the same proteins as their nuclear receptor counterparts in several systems ([@b11-ehp0112-001481]; [@b25-ehp0112-001481]; [@b34-ehp0112-001481]; [@b35-ehp0112-001481]). Therefore, it is reasonable to suggest that xenoestrogens can bind to mER and produce rapid changes in signaling, similar to E~2~. However, there are few data ([@b1-ehp0112-001481]; [@b32-ehp0112-001481]; [@b44-ehp0112-001481]; [@b45-ehp0112-001481]; [@b53-ehp0112-001481]; [@b58-ehp0112-001481]) addressing the ability of environmental estrogens to mediate nongenomic estrogenic actions, and many studies on this phenomenon have used concentrations of xenoestrogens much higher than would be found in contamination sites.

In the present study, we investigated the ability of some of these estrogen mimetics (belonging to the major classes of environmental estrogens) to produce rapid activation of ERKs via various signaling pathways in the GH~3~/B6/F10 prolactinoma cell line. We previously selected this subline for its robust expression of mER-α and its capacity for rapid E~2~-induced prolactin release ([@b35-ehp0112-001481]), and we also demonstrated that adequate levels of mER were necessary to elicit rapid ERK responses ([@b7-ehp0112-001481]). Here, we tested organochlorine pesticides \[dieldrin, endosulfan, and the DDT metabolite *o*,*p*′-dichlorodiphenylethylene (DDE)\], detergents used in plastics manufacturing (*p*-nonylphenol and bisphenol A), and the natural phytoestrogen coumestrol. The signaling pathways that we examined are generally known to initiate at the plasma membrane and go through multiple steps before converging on the ERKs. Others have associated features such as G protein involvement, Ca^2+^ influx, and epidermal growth factor receptor (EGFR) phosphorylation with downstream ERK activations, which can lead to diverse cellular functions such as cell proliferation, transformation, differentiation, and migration ([@b3-ehp0112-001481]; [@b40-ehp0112-001481]). Xenoestrogens, such as endosulfan and chlordane ([@b12-ehp0112-001481]) and nonylphenol, bisphenol A, and coumestol ([@b18-ehp0112-001481]), at relatively low (10^−9^--10^−7^ M) concentrations, can produce proliferation in other cell lines, and this function can be regulated by the xenoestrogen benzopyrene through ERK ([@b49-ehp0112-001481]), The alteration of cell proliferation, as well as other functions downstream of ERK activation, could lead to endocrine disruptions known to be caused by environmental estrogens.

To monitor signaling events leading to ERK activation, we used our fixed cell--based ELISA ([@b7-ehp0112-001481]), which allows us to analyze many samples and thus detailed time- and concentration-dependent changes in ERK phosphorylation resulting from actions of multiple xenoestrogenic compounds and specific inhibitors of signaling cascade participants. Such comparative explorations of differential signaling pathway involvement, kinetics, and potencies unique to each compound may lead to more detailed predictions about the hazards of exposure mediated through different subsets of responses related to endocrine disruption by individual xenoestrogens.

Materials and Methods
=====================

Phenol red--free Dulbecco's modified Eagle medium (DMEM) was purchased from Mediatech (Herndon, VA). Horse serum was obtained from Gibco BRL (Grand Island, NY); defined supplemented calf sera and fetal bovine sera were from Hyclone (Logan, UT). Endosulfan and DDE were purchased from Ultra Scientific (North Kingstown, RI). From Vector Laboratories (Burlingame, CA), we purchased biotinylated universal anti-mouse/rabbit IgG, Vectastain ABC-AP (avidin:biotinylated enzyme complex with alkaline phosphatase) detection systems, levamisol (endogenous alkaline phosphatase subtype inhibitor), and *para*-nitrophenol phosphate (pNpp; the substrate for our alkaline phosphatase reaction). Phospho-p44/42 ERK (pERK) monoclonal antibody (Ab), anti-mouse horseradish peroxidase--linked Ab, and lysis buffer were obtained from Cell Signaling Technology (Beverly, MA). Paraformaldehyde was from Fisher Scientific (Fair Lawn, NJ). BAPTA-AM (B-TA) was from Molecular Probes (Eugene, OR), and PP2, Ag 1468 (AG 14), and Ly294002 (Ly) were from Calbiochem (San Diego, CA). ICI 182,780 (ICI) was from Tocris (Ellisville, MO). All other reagents were purchased from Sigma Chemical Company (St. Louis, MO).

Cell culture.
-------------

Our clonal rat prolactinoma cell line GH~3~/B6/F10 was selected for high expression of mER-α ([@b35-ehp0112-001481]). Cells were routinely subcultured in DMEM containing 12.5% horse serum, 2.5% defined supplemented calf serum, and 1.5% fetal calf serum. For individual experiments, cells were deprived of steroids for 48 hr after plating by substituting DMEM containing 1% charcoal-stripped (4×) serum. All test estrogens were dissolved in ehanol (EtOH) at a 10^−2^ M concentration to create a stock solution and then diluted into experimental media to yield final concentrations from 10^−8^ to 10^−12^ M. The EtOH concentration used as the vehicle control was 0.0001%.

Fixed cell--based ELISA.
------------------------

To estimate ERK phosphorylation quantitatively, we used a cell-based ELISA, which we previously developed and described ([@b7-ehp0112-001481]). Briefly, cells (10^4^ cells/well) were plated in 96-well plates (Corning Incorporated, Corning, NY) and withdrawn from serum hormones by incubation in medium containing 1% charcoal-stripped serum for 48 hr before experiments began. The cells were next treated with hormones and estrogen mimetics for 3--30 min, and then fixed with 2% paraformaldehyde/0.2% picric acid at 4°C for 48 hr. After fixation, the cells were incubated with phosphate-buffered saline (PBS) containing 2% bovine serum albumin (BSA) and 0.1% Triton X-100 for 1 hr at room temperature (RT), and then with primary Ab against pERK (1:400 in PBS/1% BSA/0.1% Triton X-100) overnight at 4°C. After a wash with PBS, biotin-conjugated secondary Ab (1:300) in PBS/1% BSA was added for 1 hr at RT. The cells were again washed in PBS and incubated with Vectastain ABC-AP solution (100 μL/well) for 1 hr at RT, and then Vectastain alkaline phosphatase substrate (pNpp solution) with levamisole was added to each well (100 μL). Plates were incubated in the dark for 30 min at 37°C, and the signal from *para*-nitrophenol (pNp) was read at A~405~ in a model 1420 Wallac microplate reader (Perkin Elmer, Boston, MA). The pNp signal was normalized to cell number, determined by using the crystal violet (CV) assay ([@b8-ehp0112-001481]). Briefly, after washing away alkaline phosphatase reaction reagents with double-distilled H~2~O, the plate was completely dried at RT. CV solution (0.1% in water, filtered) was added at 50 μL/well, incubated for 30 min at RT, and washed out with double-distilled H~2~O. Dye was released from the cells with 50 μL/well acetic acid (10% in water) at RT for 30 min. The A~590~ signal was then read in the microplate reader.

Statistics.
-----------

Data were compared for significance of differences using Sigma Stat 3 (Jandel Scientific, San Rafael, CA) and one-way analysis of variance (significance accepted at *p* ≤0.05).

Results
=======

Xenoestrogens can cause unique time-dependent patterns of ERK phosphorylation.
------------------------------------------------------------------------------

E~2~ (10^−9^ M) produced rapid (3, 15, and 30 min after application) and bimodal (with apparent periods of dephosphorylation between activation periods) ERK phosphorylation. Xenoestrogens at 10^−9^ M also caused ERK activations but with distinct temporal patterns ([Figure 1](#f1-ehp0112-001481){ref-type="fig"}). According to these patterns, compounds could be divided into several groups. Endosulfan and nonylphenol did not cause an initial (3 min) stimulation, but instead caused only a delayed single ERK phosphorylation peak at 30 min (which we designated slow-phase-only responders). DDE and dieldrin caused a single peak of activation at 6--10 min and were unable to cause a second sustained activation at 30 min (fast-phase-only responders). Coumestrol produced a rapid response (significant by 6 min), but the phosphorylation levels never declined after the activation, as was seen with the other active compounds. Bisphenol A did not produce any significant changes from the basal level of ERK phosphorylation during the 30 min assessment time and was not examined further in this study. All active xenoestrogens produced only a monophasic activation, failing to mimic the bimodal E~2~ activation.

Xenoestrogens can be potent activators of ERK phosphorylation but with unique concentration-dependent patterns.
---------------------------------------------------------------------------------------------------------------

At optimal stimulation time points ([Figure 1](#f1-ehp0112-001481){ref-type="fig"}), different concentrations of E~2~ and xenoestrogens were compared in their ability to activate ERKs ([Figure 2](#f2-ehp0112-001481){ref-type="fig"}). E~2~ (tested at 3 min) was active in two concentration ranges: very low levels (10^−14^ M) and higher, but still physiological, levels (10^−9^--10^−8^ M). Nonylphenol and coumestrol showed similar patterns of potency, with dual ranges of activation similar to that seen with E~2~. Endosulfan was able to produce phosphorylation at almost all tested concentrations but still showed an apparent loss of activity centered on the 10^−10^ M concentration. DDE and dieldrin were not active at low concentrations (picomolar and lower) but were active in the concentration range centering on 10^−9^ M. Thus, although some subtle differences were observable between activation patterns for each compound, basically two patterns of stimulation were seen: compounds active in both the subpicomolar and nanomolar ranges (E~2~, endosulfan, nonylphenol, and coumestrol) versus compounds active only in the nanomolar range (DDE and dieldrin).

Possible pathways for ERK activation for different compounds.
-------------------------------------------------------------

To detect possible signaling pathways through which E~2~ and xenoestrogens could affect pituitary tumor cells, we used inhibitors that have been described in the literature to pinpoint various mechanisms leading to ERK phosphorylation ([@b3-ehp0112-001481]; [@b27-ehp0112-001481]). ICI and AG 14 are specific antagonists of estrogen and EGFRs, respectively. Nystatin (Nys) is a cholesterol-binding antibiotic that disrupts membrane architecture ([@b51-ehp0112-001481]). B-TA is a Ca^2+^ chelator. PP2 is a Src kinase inhibitor, and Ly is a PI3K inhibitor. An example of each type of xenoestrogen based on temporal activation patterns shown in [Figure 1](#f1-ehp0112-001481){ref-type="fig"} (fast-phase activator DDE, slow-phase activator endosulfan, and sustained-activator coumestrol) was examined for each of these inhibitor actions. All time points in their activation profiles were examined to determine when each mechanism might come into play ([Figures 3](#f3-ehp0112-001481){ref-type="fig"}--[5](#f5-ehp0112-001481){ref-type="fig"}). Inhibitor data were divided into two groups for clarity of presentation. [Figures 3A](#f3-ehp0112-001481){ref-type="fig"}, [4A](#f4-ehp0112-001481){ref-type="fig"}, and [5A](#f5-ehp0112-001481){ref-type="fig"} group together the responses to inhibitor compounds that can interfere with receptors (ERs, EGFRs) or disrupt membrane structures housing receptors: ICI, AG 14, and Nys (group A). [Figures 3B](#f3-ehp0112-001481){ref-type="fig"}, [4B](#f4-ehp0112-001481){ref-type="fig"}, and [5B](#f5-ehp0112-001481){ref-type="fig"} group together data for compounds whose substrates are mostly localized in the cell's cytoplasm or are adjacent to the cell membrane and part of the downstream signaling cascades initiated at the membrane: B-TA, PP2, and Ly (group B).

Inhibition of endosulfan-stimulated ERK activation is shown in [Figure 3](#f3-ehp0112-001481){ref-type="fig"}. In these assays, endosulfan stimulated ERK significantly only at 30 min (as in [Figure 1](#f1-ehp0112-001481){ref-type="fig"}). Only ICI and Ly inhibited the endosulfan-provoked ERK activation at 30 min. The activity of ICI implicates ER-αin this process \[because this subline does not express ER-β ([@b8-ehp0112-001481]; [@b34-ehp0112-001481])\]. However, even at times when endosulfan could not significantly elevate basal phosphorylation of ERK (3--15 min), all tested inhibitors were able to further deactivate basal ERK activity levels at some of these time points (e.g., AG 14 at 15 min; all group B compounds were effective at 3 and 15 min: PP2 at 6 and 10 min; Ly, ICI, and Nys at 6 min). Such inhibitions are xenoestrogen dependent because the inhibitors alone do not cause these dephosphorylations ([@b7-ehp0112-001481]).

DDE produced ERK activation only at 6 min ([Figure 4](#f4-ehp0112-001481){ref-type="fig"}), as expected from earlier studies ([Figure 1](#f1-ehp0112-001481){ref-type="fig"}). At this time point, ERK phosphorylation was inhibited by AG 14, PP2, and Ly. Although at other time points DDE did not raise ERK activation levels above basal, the addition of inhibitors nevertheless did lower activity to subbasal levels (all at 3 min; AG 14, PP2, and Ly at 15 min). Altogether, all tested compounds had an effect on basal ERK activity levels at some time point, but some tended to affect this outcome earlier in this time frame compared with others.

Coumestrol activated ERKs from 6 min onward in our assay (as shown in [Figure 1F](#f1-ehp0112-001481){ref-type="fig"} and in [Figure 5](#f5-ehp0112-001481){ref-type="fig"}). During the preactivation phase (3 min), basal levels of phosphorylation were further lowered by ICI, Nys, and B-TA. During the 6 min onward coumestrol activation phase, ICI was never effective at lowering ERK phosphorylation levels. AG 14 was effective at 6--15 min time points, and PP2 during the entire stimulation phase, which suggests early involvement of EGFR and Src kinase. Nys disruption of membrane structure (15--30 min) and Ly inhibition of PI3K (15 min) were effective only during these short temporal windows. B-TA's chelation of Ca^2+^ was effective only very late in this sequence, at 30 min. Therefore, most inhibitors were effective at some point, although some later than others.

Discussion
==========

An important and surprising conclusion from our studies was that all tested estrogenic compounds, except bisphenol A, elicited rapid membrane-initiated actions at very low concentrations compared with their reported potencies in classical genomic pathways ([@b18-ehp0112-001481]; [@b20-ehp0112-001481]; [@b21-ehp0112-001481]). All active compounds were able to produce rapid (3--30 min) ERK phosphorylations in the nanomolar concentration range, and some (E~2~, coumestrol, nonylphenol, and endosulfan) were also active in the subpicomolar range. Compounds from different classes of endocrine disruptors with dissimilar chemical structures (e.g., endosulfan as an organochlorine compound vs. nonylphenol as a simple phenolic detergent) can produce the same time-dependent activation pattern for ERKs. Coumestrol, a phytoestrogen, initiated a sustained ERK activation that had no temporal pattern similarity with any of the other tested compounds, including E~2~. None of the tested compounds was able to precisely repeat the E~2~ pattern of activation, which may contribute to their disruptive effects on estrogen-mediated endocrine functions.

The bimodal E~2~ time-dependent response seems to superimpose the patterns from both groups of other response-producing compounds: fast phase (during the first 10 min) and slow phase (not until 30 min). Interestingly, the most potent endocrine-disrupting chemical in genomic action assays, bisphenol A ([@b9-ehp0112-001481]; [@b41-ehp0112-001481]; [@b45-ehp0112-001481]), was unable to produce time-dependent ERK activation. However, studies in progress show that bisphenol A, although unable to trigger ERK activation, nevertheless is somewhat effective at triggering Ca^2+^ influx, resulting in prolactin secretion (Wozniak et al., unpublished data). Thus, there are likely to be specific pathways within the nongenomic signaling network that individual compounds will trigger, leading to different functional end points. Therefore, each xenoestrogenic compound must be tested for an array of possible mechanistic routes of action.

Several tested xenoestrogenic compounds (coumestrol, nonylphenol, and endosulfan) demonstrated a bimodal dose--response curve for ERK activation similar to that seen with E~2~. This is reminiscent of the same bimodal dose--response pattern reported previously for rapid prolactin release after E~2~ ([@b54-ehp0112-001481]) and E~2~-BSA ([@b55-ehp0112-001481]) treatment. The reason for this gap in dose responsiveness at intermediate concentrations is still not understood, but it is interesting that other estrogens in the present study demonstrate the same phenomenon. These very low effective doses for xenoestrogens demonstrate that many environmental contamination levels previously thought to be subtoxic may very well exert significant signal-and endocrine-disruptive effects, discernable only when the appropriate mechanism is assayed. Possible reasons for these potent effects not being noted previously are that little testing of the nongenomic pathway has been done, many tests did not examine such low concentrations, and some test conditions probably did not adequately remove endogenous estrogen levels (as we have done by use of low quantities of extensively charcoal-stripped serum) to reveal effects of these low concentrations. The potent effects we see on nongenomic signaling mechanisms could explain why concentrations previously determined to be inactive via genomic mechanisms still have toxic and teratogenic effects on wildlife ([@b5-ehp0112-001481]). Therefore, the threat levels of these compounds to wildlife, and probably humans, need to be reconsidered.

The complexity of multiple signaling pathways triggered simultaneously is probably related to the organization of ERs within membrane substructures (caveolae or membrane rafts), where they encounter many signaling machineries ([@b10-ehp0112-001481]; [@b32-ehp0112-001481]; [@b39-ehp0112-001481]). Our data indicate that the disruption of a nongenomic signaling cascade midway in its time course caused by Nys (e.g., for coumestrol) probably corresponds to disruption of this cholesterol-rich meeting place for ligands and receptors with their downstream signaling partners. Interestingly, only endosulfan effects failed to be inhibited by disruption of cholesterol-rich membrane structure, perhaps implicating different membrane subdomains as locations for the actions of different compounds. Alternatively, endosulfan signaling may move into the intracellular compartment rapidly after initiation and earlier than 3 min (and earlier time point assessment using these methods would be technically difficult).

Although here we have only directly assessed ERK activation as a signaling cascade end point, the participation of upstream signaling repertoires was implicated by our specific inhibitor assays. We found that all examined pathways can participate in ERK activation but that different xenoestrogens use different subsets of these pathways. [Table 1](#t1-ehp0112-001481){ref-type="table"} summarizes the vulnerability of E~2~- ([@b7-ehp0112-001481]), endosulfan-, DDE- and coumestrol-initiated actions to inhibitors of different signaling components. E~2~- or xenoestrogen-treated cells showed inhibitions of both stimulated ERK phosphorylation levels and background levels of phosphorylation. Our time course measurements allowed an analysis of when pathway inhibitions affected the outcome of ERK phosphorylation, and we noted whether this was very early after treatment (3 min) or later (≥6 min). Although these times are arbitrary cutoffs, they allowed us to highlight some possible temporal differences in the effects of compounds' pathways. All xenoestrogens shared activation via all pathways, although compounds differed in their timing of pathway engagement. For example, inhibitors of action via the EGFR and ER were sometimes effective only after 6 min. This could mean that the activation sequence took some time to reach the level of a receptor (EGFR is downstream) or that a unique conformation of receptors in the plasma membrane could initially prevent binding by antagonists (ER). Although all xenoestrogens shared activation via the PI3K pathway, PI3K inhibitors could not lower DDE- or coumesterol-mediated ERK phosphorylation levels until ≥6 min, so perhaps progression to this level of signaling took variable amounts of time depending upon the compound initiating the response. A possible complication to our interpretation of these data is the recent demonstration that Ly can have antiestrogenic activity by binding to ER [@b36-ehp0112-001481]).

Inhibitors also interfered with ERK phosphorylation levels that were not stimulated by xenoestrogens above untreated background levels. For example, endosulfan, which elevates ERK phosphorylation only after 30 min, still participated in a significant lowering of basal ERK phosphorylation levels at early time points. In our previous work ([@b7-ehp0112-001481]), we demonstrated that these inhibitors by themselves were unable to change basal levels of ERK phosphorylation; the present study thus shows that the presence of xenoestrogens was necessary to produce inhibitor-driven decreases below basal levels. Because ERK phosphorylation demonstrated a complex temporal fluctuation, we speculate that periods of "dephosphorylation" demonstrated by our data could be the result of desensitization of the stimulatory pathways and/or phosphatase activation. Such deactivation and reactivation profiles may be very important for specific estrogenic stimulatory effects because other hormones and regulators are known to operate in an oscillatory fashion through kinase inactivation ([@b28-ehp0112-001481]) or protein degradation ([@b31-ehp0112-001481]). However, the rapid recovery times in our pattern argue against the latter mechanism.

Wide diversity in signaling cascades leading to ERK activation can perhaps be explained by the nature of mERs and the probable necessity of their interactions with many other different signaling partners. Xenoestrogens are highly diverse in structure, and the conformation of different xenoestrogen--ER complexes could be significantly different from that of an E~2~--ER complex ([@b6-ehp0112-001481]; [@b48-ehp0112-001481]; [@b52-ehp0112-001481]). This could alter the receptor protein's surface topography and thus its interactions with partner proteins, as has been demonstrated for ligand effects on nuclear receptor interactions with coactivators and corepressors. The nature and magnitude of responses are probably a function of the conformation the receptor assumes around these diverse molecules and the repertoire of interacting proteins present in different cell types (so pituitary cell patterns may not be predictive for other cell types). The outcomes can be different and multiplex. Therefore, xenoestrogens will need to be individually examined for these complex mechanistic and functional outcomes in different tissues.

![Time-dependent changes in the phosphorylation status of ERK. E~2~ (*A*), *p*-nonylphenol (*B*), endosulfan (*C*), DDE (*D*), dieldrin (*E*), coumestrol (*F*), and bisphenol A (*G*) were applied at 10^−9^ M. Data are presented as percentage of control values, which were set to 100; *n* = 48--60 wells/point taken from three different 96-well plates.\
\*Statistically significant (*p* \< 0.05) compared with vehicle (0.0001% ethanol)-treated controls.](ehp0112-001481f1){#f1-ehp0112-001481}

![Concentration-dependent changes in the phosphorylation status of ERK. Each compound was tested at its previously determined time optimum ([Figure 1](#f1-ehp0112-001481){ref-type="fig"}): E~2~ (*A*) at 3 min, coumestrol (*B*) at 6 min, *p*-nonylphenol (*C*) and endosulfan (*D*) at 30 min, and DDE (*E*) and dieldrin (*F*) at 6 min. Data are presented as percentage (mean ± SE) of control values (which were set to 100); *n* = 78--85 wells from three different 96-well plates.\
\*Statistically significant (*p* \< 0.05) compared with vehicle (0.0001% ethanol)-treated controls.](ehp0112-001481f2){#f2-ehp0112-001481}

![Effects of different inhibitors on endosulfan-induced ERK phosphorylation. (*A*) Inhibition effects for membrane-level components ICI, Nys, and AG 14. (*B*) Effects for postmembrane signaling system components B-TA, PP2, and Ly. Cells were pretreated with inhibitors at optimal effective concentrations and for optimal times of action: 1 μM ICI for 40 min, 50 μg/mL Nys for 40 min, 10 μM B-TA for 40 min, 10 μM PP2 for 20 min, 10 μM Ly for 40 min, 250 nM AG 14 for 20 min, or 0.01% DMSO vehicle (control) for 40 min, and then stimulated with endosulfan (End) at 1 nM, before the timed pERK plate assay. Values shown are mean ± SE; *n* = 40--90 wells from three to six different 96-well plates.\
\*Statistically significant (*p* \< 0.05) compared with vehicle control. \*\*Statistically significant (*p* \< 0.05) compared with time-specific endosulfan-alone stimulated controls.](ehp0112-001481f3){#f3-ehp0112-001481}

![Effects of different inhibitors on DDE-induced ERK activation. (*A*) Inhibition effects for membrane-level components ICI, Nys, and AG 14. (*B*) Effects for postmembrane signaling system components B-TA, PP2, and Ly. Cells were pretreated with inhibitors at optimal effective concentrations and for optimal times of action: 1 μM ICI for 40 min, 50 μg/mL Nys for 40 min, 10 μM B-TA for 40 min, 10 μM PP2 for 20 min, 10 μM Ly for 40 min, 250 nM AG 14 for 20 min, or 0.01% DMSO vehicle (control) for 40 min, and then stimulated with DDE (1 nM). Values shown are mean ± SE; *n* = 45--85 wells from three to six different 96-well plates.\
\*Statistically significant (*p* \< 0.05) compared with vehicle control. \*\*Statistically significant (*p* \< 0.05) compared with time-specific DDE-stimulated controls.](ehp0112-001481f4){#f4-ehp0112-001481}

![Effects of different inhibitors on coumestrol (Coum)-induced ERK activation. (*A*) Inhibition effects for membrane levels components ICI, Nys, and AG 14. (*B*) Effects for postmembrane signaling system components B-TA, PP2, and Ly. Cells were pretreated with inhibitors at optimal effective concentrations and for optimal times of action: 1 μM ICI for 40 min, 50 μg/mL Nys for 40 min, 10 μM B-TA for 40 min, 10 μM PP2 for 20 min, 10 μM Ly for 40 min, 250 nM AG 14 for 20 min, or 0.01% DMSO vehicle (control) for 40 min, and then stimulated with coumestrol at 1 nM. Values shown are mean ± SE; *n* = 39--79 wells from three to six 96-well plates.\
\*Statistically significant (*p* \< 0.05) compared with vehicle control. \*\*Statistically significant (*p* \< 0.05) compared with time-specific coumestrol-stimulated values.](ehp0112-001481f5){#f5-ehp0112-001481}

###### 

Xenoestrogens each have unique signaling pathway inhibition patterns during rapidly initiated estrogenic actions.

  Inhibitors   E~2~   Endosulfan   DDE   Coumestrol
  ------------ ------ ------------ ----- ------------
  Ca^2+^       \+     \+           \+    \+
  Membrane     \+                  \+    \+
  Src          \+     \+           \+    (+)
  PI3K         \+     \+           (+)   (+)
  EGFR         (+)    (+)          \+    (+)
  ER           (+)    (+)          \+    \+

+, inhibition effect at 3 min; (+), inhibition effect at ≥6 min. For comparison, the E~2~ response inhibition data summarized here are taken from [@b7-ehp0112-001481]. All time points where the combination of xenoestrogen and inhibitor showed a significant reduction in ERK phosphorylation levels below the hormone-untreated background level are shown.
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